Chengdu Bofa Biotechnology

Chengdu Bofa Biotechnology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative cell-based immunotherapies for cancer. The company's core focus is its proprietary Bofa-T and Bofa-NK technology platforms, which are designed to produce highly specific and potent immune cells to target a variety of malignancies. Its lead program, Bofa-T, is a multi-target antigen-specific T cell therapy currently being evaluated in clinical trials for its efficacy against solid tumors such as lung and liver cancer. By integrating advanced research with robust manufacturing capabilities, Chengdu Bofa aims to address the limitations of current cancer treatments and improve patient outcomes. The company operates primarily within the Chinese market, collaborating with leading medical institutions for clinical translation.